Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses quality-of-life results from the phase III OlympiA study of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract GS4-09).
Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discusses findings that point to the potential benefits of using adjuvant exemestane plus ovarian function suppression (OFS) to treat premenopausal women with hormone receptor–positive early breast cancer. This conclusion came after 13 years of median follow-up on the TEXT and SOFT trials, during which this regimen was compared with tamoxifen and OFS (Abstract GS2-05).
Charles Coombes, MD, PhD, of Imperial College, London, discusses study results on samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor–positive HER2-negative breast cancer. The combination of agents has demonstrated evidence of anti-tumor activity for patients who have progressed on their prior CDK4/6 inhibitor treatment (Abstract GS3-10).
Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses the final phase III results of KEYNOTE-355, which showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (Abstract GS1-02 ).
Sara A. Hurvitz, MD, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. T-DXd showed superior progression-free survival across subgroups of patients previously treated with trastuzumab and a taxane, including those with brain metastases (Abstract GS3-01).
Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer. Dr. Gnant also talks about whether any correlative studies hint at patient subgroups that this regimen may benefit (Abstract GS1-07) .
